INPLASY PROTOCOL

Corresponding author:
Yiqun Han

hanyiqun803@163.com

Author Affiliation:
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.

Support: None.

Review Stage at time of this submission: Piloting of the study selection process.

Conflicts of interest: None declared.

Assessment of optimal choice as first-line therapy for patients with triple-negative breast cancer: a Bayesian analysis

Han, Y[1]; Wang, J[2]; Xu, B[3].

Review question / Objective: To assess the optimal first-line treatment for metastatic triple-negative breast cancer.
Condition being studied: Metastatic triple-negative breast cancer.
Intervention: chemotherapy-based regimens
Information sources: PubMed, Embase, Web of Science.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 09 August 2021 and was last updated on 09 August 2021 (registration number INPLASY202180030).

INTRODUCTION

Review question / Objective: To assess the optimal first-line treatment for metastatic triple-negative breast cancer.

Condition being studied: metastatic triple-negative breast cancer.

METHODS

Participant or population: Patients with metastatic triple-negative breast cancer.

Intervention: Chemotherapy-based regimens.

Comparator: chemotherapy.

Study designs to be included: RCTs.

Eligibility criteria: RCTs, comparators, first-line treatment.

Information sources: PubMed, Embase, Web of Science.

Main outcome(s): Progression-free survival.

Additional outcome(s): Overall survival, safety profiles.

Quality assessment / Risk of bias analysis: Cochrane Handbook.

Strategy of data synthesis: network meta-analysis.

Subgroup analysis: None.

Sensitivity analysis: None.

Country(ies) involved: China.

Keywords: metastatic triple-negative breast cancer; first-line therapy.

Contributions of each author:
Author 1 - Yiqun Han.
Email: hanyiqun803@163.com
Author 2 - Jiayu Wang.
Email: wangjiayu8778@sina.com
Author 3 - Binghe Xu.
Email: xubingheBM@163.com